The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients
Official Title: A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid and Circulating Tumor Cell Measurements in Patients With HER2-negative Metastatic Breast Cancer Without Bone Metastasis
Study ID: NCT01129336
Brief Summary: This study will evaluate zoledronic acid's anti-cancer effects and Circulating Tumor Cell (CTCs) measurements in patients with HER2-negative metastatic breast cancer without bone metastasis.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Highlands Oncology Group, Fayetteville, Arkansas, United States
Clopton Clinic, Jonesboro, Arkansas, United States
Hematology Oncology Services of Arkansas, Little Rock, Arkansas, United States
Kaiser Permanente Medical Group Kaiser Permanente - Hawaii, Anaheim, California, United States
Wilshire Oncology Medical Group, La Verne, California, United States
Loma Linda University Loma Linda Cancer Center, Loma Linda, California, United States
Hematology and Medical Oncology, Waterbury, Connecticut, United States
Florida Cancer Specialists DeptofFloridaCancerSpecialists, Fort Myers, Florida, United States
Lakeland Regional Cancer Center Dept. of Lakeland Regional, Lakeland, Florida, United States
Space Coast Medical Associates, Titusville, Florida, United States
Kootenai Medical Center Kootenai Medical Center, Coeur d'Alene, Idaho, United States
Oncology Specialists, SC Lutheran General Cancer Instit, Park Ridge, Illinois, United States
Cancer Center of Kansas, Witchita, Kansas, United States
Park Nicollet Institute Dept. of Park Nicollet, St. Louis Park, Minnesota, United States
St. John's Mercy Medical Center St. John's Mercy Med Ctr, St. Louis, Missouri, United States
Hematology Oncology Centers of the Northern Rockies Hema Onc Ctr N. Rockies (4, Billings, Montana, United States
Southeast Nebraska Oncology Cancer Center, Lincoln, Nebraska, United States
Reno Oncology Consultants, Reno, Nevada, United States
Somerset Hematology Oncology Associates Somerset Hema Oncol Assoc (2), Somerset, New Jersey, United States
Cooper Cancer Center, Voorhees, New Jersey, United States
NYU Langone Arena Oncology, Lake Success, New York, United States
Marion L. Shepard Cancer Center, Washington, North Carolina, United States
Piedmont Hematology and Oncology Associates Piedmont Hem/Onc Assoc (2), Winston-Salem, North Carolina, United States
Hematology Oncology Center, Inc., Elyria, Ohio, United States
Milton S Hershey Medical Center Hershey Medical Center (4), Hershey, Pennsylvania, United States
Berks Hematology Oncology, West Reading, Pennsylvania, United States
Abington Hematology Oncology Associates, Inc, Willow Grove, Pennsylvania, United States
The West Clinic, Memphis, Tennessee, United States
Sarah Cannon Research Institute, Nashville, Tennessee, United States
South Texas Oncology and Hematology, PA South Texas Oncology (2), San Antonio, Texas, United States
East Texas Medical Center Cancer Institute Tyler Hem/Onc (3), Tyler, Texas, United States
Medical Oncology & Hematology Associates of Northern VA Med. Onc&Hem Assoc. of No.VA, Reston, Virginia, United States
Northwest Medical Specialties, Tacoma, Washington, United States
Name: Novartis Pharmaceuticals
Affiliation: Novartis Pharmaceuticals
Role: STUDY_DIRECTOR